Latest Profitability News

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

Cann Group Limited has reported a strong operational update, exceeding its medicinal cannabis production targets and significantly reducing costs, while expanding sales channels and securing fresh capital to bolster its balance sheet.

Findi Limited has reported record FY25 financial results, exceeding revenue guidance and expanding its ATM and digital financial services footprint across India. The company is advancing towards a Payments Bank license and plans an IPO of its Indian subsidiary by the end of 2026.

Findi Limited has reported record FY25 revenue and EBITDA growth, driven by key acquisitions and expanded ATM and digital payment networks across India. The company’s strengthened balance sheet and contract wins set the stage for its subsidiary’s planned 2026 IPO.

Findi Ltd reports flat revenue and a 15% rise in EBITDA but swings to a $12.5 million net loss for FY2025, driven by strategic capital raises and refinancing in its Indian subsidiary.

Aspermont Limited reports steady subscription growth with $11.2 million in annual recurring revenue despite a dip in total revenue, while gearing up for new data product launches and an IPO.

Baumart Holdings has completed a modest capital raise through a rights issue, securing $182,303 before costs, with plans to issue additional shortfall shares to bolster its funding position.

Aspermont has reported a 6% rise in revenue and a 25% jump in net profit for the half year ending March 2025, yet its net tangible assets per share have declined and dividends remain on hold.

New Zealand King Salmon has lowered its FY26 harvest volume and earnings guidance due to slower fish growth linked to subdued feed outs during warmer months. The company aims to rebuild biomass and improve future harvests with new strategies.

Pacific Edge Limited has launched a NZ$20 million capital raise to bolster its cash reserves amid the loss of Medicare coverage for its bladder cancer diagnostic tests, aiming to accelerate US market adoption and support new product development.

8I Holdings Limited reported a net loss of S$1.09 million for FY2025, impacted by a sharp decline in investment gains due to global market volatility and new U.S. tariffs. The Group remains focused on a conservative, value-driven investment strategy despite challenging conditions.

Hancock & Gore Limited reported a statutory net loss of $3.18 million for the half-year ended 31 March 2025, impacted by unrealised investment losses despite steady dividend income from its school uniform subsidiary. The company declared a fully franked interim dividend of 1 cent per share.